Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia 1Head and Neck Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 81fludarabine phosphate 77Peripheral Blood Stem Cell Transplantation 62Mycophenolic Acid 55Tacrolimus 54Whole-Body Irradiation 52Busulfan 51Antilymphocyte Serum 45Cyclosporine 41fludarabine 36Methotrexate 32Filgrastim 32Melphalan 30Radiotherapy 25Methylprednisolone 19Cytarabine 17Cord Blood Stem Cell Transplantation 17Sirolimus 15Azacitidine 15Granulocyte Colony-Stimulating Factor 14Alemtuzumab 14thymoglobulin 13Flow Cytometry 13Etoposide 13Cyclosporins 13Specimen Handling 10Biopsy 10Thiotepa 9Psychiatric Rehabilitation 9Decitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Myeloproliferative Disorders × zileuton × Clear all
NCT01130688 2015-05-27

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

University of Massachusetts, Worcester

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡